Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T12:05:24.747Z.
Calculation as of: 2026-10-06T12:05:24.747Z.
Quote observation: 2026-10-05T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6ac0f7718e38414e938d0d293bbdd3741326646c7ebae4135e2c8e12d98e3a9c
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$922.50M
EV/FCF Ratio
N/A
TTM Avg
14.36x
3Y Avg
10.42x
5Y Avg
10.42x
Market Cap
$903.13M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$867.60M
EV/FCF Ratio
N/A
TTM Avg
10.33x
3Y Avg
10.33x
5Y Avg
10.33x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aktis Oncology, Inc. (AKTS) | $989.05M | N/A | N/A | N/A | N/A |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $985.79M | N/A | N/A | N/A | N/A |
| CeriBell, Inc. (CBLL)vs › | $943.26M | N/A | N/A | N/A | N/A |
| Teladoc Health, Inc. (TDOC)vs › | $1.05B | 5.85x | 6.81x | 8.38x | 15.98x |
| Arbutus Biopharma Corp (ABUS)vs › | $922.50M | N/A | 14.36x | 10.42x | 10.42x |
| Bioventus Inc. (BVS)vs › | $915.95M | 12.20x | 13.69x | 60.52x | 99.98x |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $903.13M | N/A | N/A | N/A | N/A |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $867.60M | N/A | 10.33x | 10.33x | 10.33x |
| Apnimed, Inc. (APMD)vs › | $866.15M | N/A | N/A | N/A | N/A |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.12B | 10.36x | 12.48x | 15.43x | 19.92x |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
